Item 8.01 Other Events.

As previously disclosed, on August 27, 2021, the Company and certain of its wholly owned subsidiaries completed the divestiture of the Company's legacy products business (the "Legacy Business"). The divestiture was consummated through the sale of the equity interests of certain of the Company's indirect subsidiaries and other assets comprising the Legacy Business to Acella Holdings, LLC.

Osmotica Pharmaceuticals plc (the "Company") is filing this Current Report on Form 8-K to recast its consolidated financial statements in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2020 that was previously filed with the Securities and Exchange Commission (the "SEC") on March 30, 2021 (the "2020 Annual Report") to reflect the presentation of the Legacy Business as discontinued operations and to update and supersede the risk factors and management's discussion and analysis of financial condition and results of operations included in the 2020 Annual Report.

We have revised the following items of the 2020 Annual Report (collectively, the "Revised Sections") to reflect the retrospective revisions described above:

? Exhibit 99.1: Part I, Item 1A. Risk Factors;

? Exhibit 99.2: Part II, Item 7. Management's Discussion and Analysis of

Financial Condition and Results of Operations; and

? Exhibit 99.3: Part II, Item 8. Financial Statements and Supplementary Data.

This report does not reflect events occurring after the March 30, 2021 filing date of the 2020 Annual Report and does not modify or update disclosures therein except to reflect the Legacy Business as discontinued operations and to reflect the Company's ability to continue as a going concern. For developments since the filing of the 2020 Annual Report, refer to the Company's Quarterly Reports on Form 10-Q for the quarters ended March 31, 2021 and June 30, 2021 and its Current Reports on Form 8-K filed subsequent to the 2020 Annual Report.

Information contained in Exhibits 99.1, 99.2 and 99.3 should be read in conjunction with and as a supplement to information contained in the 2020 Annual Report. For information on events occurring since the filing of the 2020 Annual Report, please refer to the Company's subsequent filings with the SEC.

Item 9.01 Financial Statements and Exhibits.

(b)

The information set forth in Item 8.01 of this Current Report is incorporated herein by reference in its entirety.





(d)

Exhibit
 Number                            Description of Document

23.1          Consent of Ernst & Young LLP

99.1          Part I, Item 1A. Risk Factors

              Part II, Item 7. Management's Discussion and Analysis of Financial
99.2        Condition and Results of Operations

99.3          Part II, Item 8. Financial Statements and Supplementary Data

101.INS     XBRL Instance Document

101.SCH     XBRL Taxonomy Extension Schema Document

101.CAL     XBRL Taxonomy Extension Calculation Linkbase Document

101.LAB     XBRL Taxonomy Extension Label Linkbase Document

101.PRE     XBRL Taxonomy Extension Presentation Linkbase Document

101.DEF     XBRL Taxonomy Extension Definition Linkbase Document

104         Cover Page Interactive Data File (formatted as Inline XBRL)

© Edgar Online, source Glimpses